TY - JOUR
T1 - Is Tissue Still the Issue?
T2 - The Promise of Liquid Biopsy in Uveal Melanoma
AU - de Bruyn, Daniël P
AU - Beasley, Aaron B
AU - Verdijk, Robert M
AU - van Poppelen, Natasha M
AU - Paridaens, Dion
AU - de Keizer, Ronald O B
AU - Naus, Nicole C
AU - Gray, Elin S
AU - de Klein, Annelies
AU - Brosens, Erwin
AU - Kiliç, Emine
PY - 2022/2/21
Y1 - 2022/2/21
N2 - Uveal melanoma (UM) is the second most frequent type of melanoma. Therapeutic options for UM favor minimally invasive techniques such as irradiation for vision preservation. As a consequence, no tumor material is obtained. Without available tissue, molecular analyses for gene expression, mutation or copy number analysis cannot be performed. Thus, proper patient stratification is impossible and patients' uncertainty about their prognosis rises. Minimally invasive techniques have been studied for prognostication in UM. Blood-based biomarker analysis has become more common in recent years; however, no clinically standardized protocol exists. This review summarizes insights in biomarker analysis, addressing new insights in circulating tumor cells, circulating tumor DNA, extracellular vesicles, proteomics, and metabolomics. Additionally, medical imaging can play a significant role in staging, surveillance, and prognostication of UM and is addressed in this review. We propose that combining multiple minimally invasive modalities using tumor biomarkers should be the way forward and warrant more attention in the coming years.
AB - Uveal melanoma (UM) is the second most frequent type of melanoma. Therapeutic options for UM favor minimally invasive techniques such as irradiation for vision preservation. As a consequence, no tumor material is obtained. Without available tissue, molecular analyses for gene expression, mutation or copy number analysis cannot be performed. Thus, proper patient stratification is impossible and patients' uncertainty about their prognosis rises. Minimally invasive techniques have been studied for prognostication in UM. Blood-based biomarker analysis has become more common in recent years; however, no clinically standardized protocol exists. This review summarizes insights in biomarker analysis, addressing new insights in circulating tumor cells, circulating tumor DNA, extracellular vesicles, proteomics, and metabolomics. Additionally, medical imaging can play a significant role in staging, surveillance, and prognostication of UM and is addressed in this review. We propose that combining multiple minimally invasive modalities using tumor biomarkers should be the way forward and warrant more attention in the coming years.
UR - https://www.mendeley.com/catalogue/41c62f69-8a3f-3748-9a86-1b41dc7f0c44/
U2 - 10.3390/biomedicines10020506
DO - 10.3390/biomedicines10020506
M3 - Review article
C2 - 35203714
SN - 2227-9059
VL - 10
SP - 506
JO - Biomedicines
JF - Biomedicines
IS - 2
ER -